Sign In

Cara Weismann

Director, Program of Excellence in MPS Diseases, Orphan Disease Center, Gene Therapy Program, University of Pennsylvania

Cara M. Weismann, Ph.D., is the Director of the Program of Excellence in Mucopolysaccharidosis (MPS) Diseases at the Orphan Disease Center, part of the Gene Therapy Program at the University of Pennsylvania. Her work focuses on advancing therapies for lysosomal storage diseases, including MPS, which are rare genetic disorders caused by enzyme deficiencies. These diseases often involve multi-systemic complications, and Dr. Weismann's efforts include developing innovative treatments such as gene therapy to address central nervous system involvement in these conditions.123

Highlights

Jan 16 · curegm1.org
Home - CureGM1
Jan 7 · curegm1.org
Cure GM1 January 2025 Catalyst - CureGM1
Feb 16 · bulletin.wustl.edu
People of the School of Medicine - Washington University in St.Louis
Our Team - Orphan Disease Center - University of Pennsylvania
Our Team - Orphan Disease Center - University of Pennsylvania
Jan 1 · med.upenn.edu
Faculty | The Weissman Lab
Mixing genome annotation methods in a comparative analysis ...
Dec 15 · fliphtml5.com
Courage - December 2020 - Flipbook by National MPS Society
Cara Bohon - Stanford Profiles

Related Questions

What are Cara M. Weismann's main research interests?
How is Cara M. Weismann contributing to the treatment of MPS diseases?
What is the significance of the Orphan Disease Center at the University of Pennsylvania?
Can you provide more details about the Gene Therapy Program at the University of Pennsylvania?
What are the latest advancements in gene therapy for MPS diseases?
Cara Weismann
Cara Weismann, photo 1
Cara Weismann, photo 2
Add to my network

Location

Philadelphia, Pennsylvania